- ISIN
- US64049M2098
- CUSIP
- 64049M209
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Nov 2, 1999
Highlights
- Market Cap
- $289.33M
- Enterprise Value
- $556.55M
- EPS (TTM)
- -$3.86
- Total Revenue (TTM)
- $745.97M
- Gross Profit (TTM)
- $314.28M
- EBITDA (TTM)
- -$50.56M
- Year Range
- $4.72 - $13.74
- Target Price
- $13.00
- ROA (TTM)
- -7.37%
- ROE (TTM)
- -11.97%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NEO Performance Chart
NeoGenomics, Inc. (NEO) is down 4.8% since the beginning of the year. At $11 per share, NEO is trading 18.5% below its 52-week high of $14. Investors who bought $1,000 worth of NEO shares 5 years ago would now be looking at an investment worth $250.
Loading charts...
Returns By Period
NeoGenomics, Inc. (NEO) has returned -4.76% so far this year and 60.00% over the past 12 months. Over the last ten years, NEO has returned 3.42% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
NeoGenomics, Inc.
- 1D
- 0.63%
- 1M
- 21.34%
- YTD
- -4.76%
- 6M
- -9.82%
- 1Y
- 60.00%
- 3Y*
- -12.42%
- 5Y*
- -24.24%
- 10Y*
- 3.42%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
NEO Monthly Returns History
Based on dividend-adjusted daily data since Mar 16, 2004, NEO's average daily return is +0.20%, while the average monthly return is +2.60%. At this rate, an investment would double in approximately 2.3 years.
Historically, 51% of months were positive and 49% were negative. The best month was Aug 2025 with a return of +81.4%, while the worst month was Mar 2022 at -43.3%. The longest winning streak lasted 11 consecutive months, and the longest losing streak was 10 months.
On a daily basis, NEO closed higher 45% of trading days. The best single day was Mar 17, 2004 with a return of +97.7%, while the worst single day was Mar 22, 2004 at -37.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.55% | -18.49% | -24.52% | 24.80% | 13.61% | 6.46% | -4.76% | ||||||
| 2025 | -13.23% | -30.14% | -5.01% | -32.61% | 13.84% | 0.41% | -33.79% | 81.40% | -12.07% | 26.55% | 23.85% | -2.81% | -28.64% |
| 2024 | -8.22% | 5.05% | 0.77% | -11.45% | -1.51% | 1.17% | 27.83% | -6.82% | -10.71% | -7.86% | 30.46% | -7.05% | 1.85% |
| 2023 | 28.57% | 41.84% | 3.32% | -16.03% | 17.51% | -6.46% | 7.84% | -13.27% | -18.16% | 13.98% | 29.60% | -10.95% | 75.11% |
| 2022 | -33.94% | -5.01% | -43.25% | -22.22% | -10.90% | -3.21% | 24.17% | -0.69% | -14.33% | -11.67% | 47.40% | -17.57% | -72.92% |
| 2021 | -1.52% | -3.87% | -5.38% | 1.58% | -16.25% | 10.09% | 2.06% | 5.47% | -0.78% | -4.64% | -25.52% | -0.41% | -36.63% |
Benchmark Metrics
NeoGenomics, Inc. has an annualized alpha of 55.11%, beta of 0.72, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since March 16, 2004.
- This stock captured 133.41% of S&P 500 Index gains and 108.16% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 55.11%
- Beta
- 0.72
- R²
- 0.02
- Upside Capture
- 133.41%
- Downside Capture
- 108.16%
Return for Risk
Risk / Return Rank
NEO ranks 70 for risk / return — better than 70% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NeoGenomics, Inc. (NEO) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NEO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.02 | ||
| Sortino ratioReturn per unit of downside risk | -1.04 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.37 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 1.32 | 2.78 | -1.46 |
| Martin ratioReturn relative to average drawdown | 2.89 | 12.44 | -9.55 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NeoGenomics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NeoGenomics, Inc. was 91.92%, occurring on Jul 31, 2025. The portfolio has not yet recovered.
The current NeoGenomics, Inc. drawdown is 81.30%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -91.92%Jul 2025 | 4y 5mo | — | 5y 4moFeb 2021 - now |
2006 bear market2006 | -85.29%Jan 2006 | 1y 10mo | 6mo 15d | 2y 4moMar 2004 - Aug 2006 |
Financial crisis2007–2009 | -72.14%Dec 2008 | 2y 1mo | 6mo 29d | 2y 8moNov 2006 - Jul 2009 |
2010 bear market2010 | -52.38%Aug 2010 | 1y 26d | 1y 11mo | 3y 3dJul 2009 - Jul 2012 |
2013 bear market2013 | -49.64%Aug 2013 | 4mo 19d | 4mo 24d | 9mo 13dApr 2013 - Jan 2014 |
Drawdown Indicators
| NEO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.92% | -56.78% | -35.14% |
Max Drawdown (1Y)Largest decline over 1 year | -45.61% | -9.10% | -36.51% |
Max Drawdown (3Y)Largest decline over 3 years | -76.65% | -18.90% | -57.75% |
Max Drawdown (5Y)Largest decline over 5 years | -90.78% | -25.43% | -65.35% |
Max Drawdown (10Y)Largest decline over 10 years | -91.92% | -33.92% | -58.00% |
Current DrawdownCurrent decline from peak | -81.30% | -1.80% | -79.50% |
Average DrawdownAverage peak-to-trough decline | -36.96% | -10.71% | -26.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.81% | 2.03% | +18.78% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NeoGenomics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NeoGenomics, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NEO relative to other companies in the Diagnostics & Research industry. Currently, NEO has a P/S ratio of 0.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NEO in comparison with other companies in the Diagnostics & Research industry. Currently, NEO has a P/B value of 0.3. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NEO
Add NeoGenomics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NEO